A decade of immune-checkpoint inhibitors in cancer therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy

Ren, Y., Yue, Y., Li, X., Weng, S., Xu, H., Liu, L., Cheng, Q., Luo, P., Zhang, T., Liu, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113147 · Cited by 17

Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer

Sung, J., & Cheong, J. (2022) · Cancers · doi:10.3390/cancers14133191 · Cited by 16

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Ramlee, S., Hulse, D., Bernatowicz, K., Pérez-López, R., Sala, E., & Aloj, L. (2022) · Cancers · doi:10.3390/cancers14153656 · Cited by 16

Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy

O’Leary, K. A., Bates, A. M., Jin, W. J., Burkel, B. M., Sriramaneni, R. N., Emma, S. E., Nystuen, E. J., Sumiec, E. G., Ponik, S. M., Morris, Z. S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01671-y · Cited by 18

SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function

Guo, Y., Ke, S., Xie, F., Chen, J., Liu, X., Wang, Z., Xu, D., Shen, Y., Zhao, G., Zhao, W., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03488-2 · Cited by 15

Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia

Tenuta, M., Pandozzi, C., Sciarra, F., Campolo, F., Gelibter, A. J., Sirgiovanni, G., Cortesi, E., Lenzi, A., Isidori, A. M., Sbardella, E., et al. (2023) · Cancers · doi:10.3390/cancers15143592 · Cited by 14

Harnessing IL-27: challenges and potential in cancer immunotherapy

Maleki, A. H., Rajabivahid, M., Khosh, E., Khanali, Z., Tahmasebi, S., & Ghorbi, M. D. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01562-w · Cited by 14

Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers

Li, D., & Rudloff, U. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2504376 · Cited by 15

Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages

Cheng, H., Li, S., Liu, H., Yan, M., Wang, J., Huang, J., Liu, S., Yang, Y., Cao, X., Cui, P., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02140-2 · Cited by 14

Biochemical signals from the extracellular matrix in inflammation and tumour immunology

Sorokin, L. M. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-025-01248-0 · Cited by 14

Toward Targeted Therapies in Oesophageal Cancers: An Overview

Bregni, G., & Beck, B. (2022) · Cancers · doi:10.3390/cancers14061522 · Cited by 15

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Hernandez, R., & Malek, T. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878377 · Cited by 15

Immune checkpoint molecules in prevention and development of asthma

Kanannejad, Z., Soleimanian, S., Ghahramani, Z., Sepahi, N., Mohkam, M., Alyasin, S. S., & Kheshtchin, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070779 · Cited by 14

Melanoma—the therapeutic considerations in the clinical practice

Adeleke, S. M., Okoli, S., Augustine, A., Galante, J. R., Agnihotri, A., Uccello, M., Ghose, A., Moschetta, M., & Boussios, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1432 · Cited by 14

Radiation combined with ultrasound and microbubbles: A potential novel strategy for cancer treatment

Sharma, D., Leong, K. X., Moore-Palhares, D., & Czarnota, G. J. (2023) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2023.04.007 · Cited by 16

The Landscape of Adoptive Cellular Therapies in Ovarian Cancer

Davis, L., Miller, R. E., & Wong, Y. N. S. (2023) · Cancers · doi:10.3390/cancers15194814 · Cited by 14

Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic

Alqurashi, Y. E. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155124 · Cited by 15

New insights into the role of mast cells as a therapeutic target in cancer through the blockade of immune checkpoint inhibitors

Ribatti, D. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1373230 · Cited by 14

The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

D’Aniello, A., Bene, A. D., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Maro, S. D., & Messere, A. (2024) · Journal of Peptide Science · doi:10.1002/psc.3596 · Cited by 14

Dissecting the stability of Atezolizumab with renewable amino acid-based ionic liquids: Colloidal stability and anticancer activity under thermal stress

Alkhawaja, B. A., Al‐Akayleh, F., Al-Rubaye, Z., AlDabet, G., Bustami, M., Smairat, M., Agha, A. S. A. A., Nasereddin, J., Qinna, N. A., Michael, A., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132208 · Cited by 14

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune‐related adverse events of immune checkpoint inhibitors

Lin, L., Houwink, A. P. I., van Dieren, J. M., Wolthuis, E. K., van Thienen, J. V., van der Heijden, M. S., Haanen, J. B. A. G., Beijnen, J. H., & Huitema, A. D. R. (2024) · Cancer Medicine · doi:10.1002/cam4.7302 · Cited by 13

Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies

Zhang, X., Li, Z., Xiao, J., Hao, P., Mo, J., Zheng, X., Geng, Y., & Ye, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401649 · Cited by 14

Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy

Maliah, A., Santana-Magal, N., Parikh, S., Gordon, S., Reshef, K., Sade, Y., Khateeb, A., Richter, A., Gutwillig, A., Parikh, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52079-x · Cited by 14

Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies

Jiménez-Labaig, P., Mohamed, F., Tan, N., Sanna, I., Bairi, K. E., Khan, S. Z., Akhade, A., Amaral, T. M. S., Trapani, D., Patel, A. K., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115564 · Cited by 14

Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?

Lettieri, S., Oggionni, T., Lancia, A., Bortolotto, C., & Stella, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062882 · Cited by 14

Neurological Immunotoxicity from Cancer Treatment

Wesley, S. F., Haggiagi, A. M., Thakur, K. T., & Jager, P. L. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136716 · Cited by 15

Identification of the Marine Alkaloid Lepadin A as Potential Inducer of Immunogenic Cell Death

Nuzzo, G., Gallo, C., Crocetta, F., Romano, L., Barra, G., Senese, G., dell’Isola, M., Carbone, D., Tanduo, V., Albiani, F., et al. (2022) · Biomolecules · doi:10.3390/biom12020246 · Cited by 14

New Insights into Immunotherapy for Gynecological Cancer

Kobori, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144198 · Cited by 14

The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients

Germani, M. M., Carullo, M., Boccaccino, A., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14184453 · Cited by 14

Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer

Lam, T., Mastos, C., Sloan, E. K., & Halls, M. L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108331 · Cited by 14

Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity

Saadi, W., Fatmi, A., Pallardó, F. V., García‐Giménez, J. L., & Mena, S. (2022) · Cancers · doi:10.3390/cancers15010184 · Cited by 15

COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

Dipasquale, A., Persico, P., Lorenzi, E., Rahal, D., Santoro, A., & Simonelli, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001870 · Cited by 15

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial

Aronson, S. L., Thijssen, B., López‐Yurda, M., Koole, S. N., van der Leest, P., León‐Castillo, A., Harkes, R., Seignette, I. M., Sanders, J., Alkemade, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58440-y · Cited by 13

JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study

Habib, R., Miller, W. H., Papadopoulos, T., Rincon, S. V. D., Berger, C., Molina, M. F., Hudson, M., & Esfahani, K. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013214 · Cited by 13

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas

Porcellato, I., Mecocci, S., Brachelente, C., Cappelli, K., Armando, F., Tognoloni, A., Chiaradia, E., Stefanetti, V., Mechelli, L., Pepe, M., et al. (2021) · Animals · doi:10.3390/ani11072121 · Cited by 13

Enhancing Adoptive Cell Therapy by T Cell Loading of SHP2 Inhibitor Nanocrystals before Infusion

Li, X., Halldórsdóttir, H. R., Weller, S., Colliander, A., Bak, M., Kempen, P. J., Clergeaud, G., & Andresen, T. L. (2022) · ACS Nano · doi:10.1021/acsnano.2c03311 · Cited by 13

Anti-Alphaviral Alkaloids: Focus on Some Isoquinolines, Indoles and Quinolizidines

Seteyen, A.-L. S., Girard-Valenciennes, E., Septembre‐Malaterre, A., Gasque, P., Guiraud, P., & Sélambarom, J. (2022) · Molecules · doi:10.3390/molecules27165080 · Cited by 13

Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory

El‐Hajjar, M., Gerhardt, L., Hong, M. M. Y., Krishnamoorthy, M., Figueredo, R., Zheng, X., Koropatnick, J. D., & Vareki, S. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.025 · Cited by 13

Intracellular radar: Understanding γδ T cell immune surveillance and implications for clinical strategies in oncology

Cherry, A. B. C., Gherardin, N. A., & Sikder, H. I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011081 · Cited by 12

Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis

Crump, L. S., Kines, K. T., Richer, J. K., & Lyons, T. R. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00189.2022 · Cited by 14

Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis

Wong, A., Riley, M., Zhao, S., Wang, J. G., Esguerra, V., Li, M., Lopez, G., Otterson, G. A., Kendra, K. L., Presley, C. J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03373-y · Cited by 13

A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma

Graves, L. A., Jeck, W. R., & Grilley‐Olson, J. E. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01054-7 · Cited by 14

Predictive value of CCL2 in the prognosis and immunotherapy response of glioblastoma multiforme

Deng, L., Ren, J., Li, B., Wang, Y., Jiang, N., Wang, Y., & Cui, H. (2023) · BMC Genomics · doi:10.1186/s12864-023-09674-x · Cited by 13

Update on current and new potential immunotherapies in breast cancer, from bench to bedside

Alaluf, E., Shalamov, M. M., & Sonnenblick, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287824 · Cited by 12

Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy

Xiao, L., Eastham, J., Giltnane, J. M., Zou, W., Zijlstra, A., Tabatsky, E., Banchereau, R., Chang, C., Nabet, B. Y., Patil, N. S., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6274 · Cited by 13

Evolving concepts in meningioma management in the era of genomics

Hsieh, A. L., Bi, W. L., Ramesh, V., Brastianos, P. K., & Plotkin, S. R. (2024) · Cancer · doi:10.1002/cncr.35279 · Cited by 13

Mechanistic insights into medulloblastoma relapse

Peterson, K. D., Turos‐Cabal, M., Salvador, A., Palomo-Caturla, I., Howell, A. J., Vieira, M. E., Greiner, S. M., Barnoud, T., & Rodríguez‐Blanco, J. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108673 · Cited by 17

Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

Pala, L., Pagan, E., Sala, I., Oriecuia, C., Oliari, M., Pas, T. M. D., Specchia, C., Cocorocchio, E., Zattarin, E., Rossi, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102681 · Cited by 13

Huang-Jin-Shuang-Shen Decoction promotes CD8+ T-cell-mediated anti-tumor immunity by regulating chemokine CXCL10 in gastric cancer

Yang, C., Xu, X., Wu, M., Zhao, Z., Feng, Y., Liang, W., Chu-yun, X., Jiang, T., & Zhang, G. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156065 · Cited by 13

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Khan, M., Nasim, M., Feizy, M., Parveen, R., Gull, A., Khan, S. M., & Ali, J. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.022 · Cited by 13

Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma

Farshadi, E. A., Wang, W., Mohammad, F., van der Oost, E., Doukas, M., van Eijck, C. H. J., van de Werken, H. J. G., & Katsikis, P. D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75888-y · Cited by 13

PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer

Shobab, L. A., Al-Souri, D., Mathews, L., McCoy, M., Kuenstner, W., Hubbard, G. K., Kumari, S., Chou, J., Lee, W., Rosen, J. E., et al. (2024) · Cancers · doi:10.3390/cancers16213632 · Cited by 14

Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors

Moik, F., Riedl, J. M., Barth, D. A., Berton, F., Fink, M. K., Englisch, C., Höeller, C., Fuereder, T., Ay, L., Pabinger, I., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.09.007 · Cited by 13

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening

Zhao, D., Deshpande, R. P., Wu, K., Tyagi, A., Sharma, S., Wu, S.-Y., Xing, F., O’Neill, S. S., Ruiz, J., Lyu, F., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101100 · Cited by 13

Engineering Modular Peptide Nanoparticles for Ferroptosis‐Enhanced Tumor Immunotherapy

Wu, B., Yang, X., Kong, N., Liang, J., Li, S., & Wang, H. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202421703 · Cited by 13

Self-healable and pH-responsive spermidine/ferrous ion complexed hydrogel Co-loaded with CA inhibitor and glucose oxidase for combined cancer immunotherapy through triple ferroptosis mechanism

Nie, T., Fang, Y., Zhang, R., Cai, Y., Wang, X., Jiao, Y., & Wu, J. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.01.005 · Cited by 13

Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches

Khan, A., Zakirullah, Z., Wahab, S., & Hong, S. (2025) · Virology Journal · doi:10.1186/s12985-025-02622-z · Cited by 13

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy

Hu, Z., Li, S., He, H., Pan, W., Liu, T., Liang, H., Xu, C., Lu, B., Tao, C., Qi, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02510 · Cited by 13

The Complexity of Malignant Glioma Treatment

Kampers, L. F. C., Metselaar, D. S., Vinci, M., Scirocchi, F., van Zanten, S. E. M. V., Eyrich, M. K., Biassoni, V., Hulleman, E., Karremann, M., Stücker, W., et al. (2025) · Cancers · doi:10.3390/cancers17050879 · Cited by 15

Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner

Joseph, G. J., Vecchi, L. A., Uppuganti, S., Kane, J. F., Durdan, M., Hill, P., McAdoo, A., Tanaka, H., Kell, D. M., Searcy, M. B., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf055 · Cited by 15

The Potential of T Cell Factor 1 in Sustaining CD8+ T Lymphocyte-Directed Anti-Tumor Immunity

Jung, S., & Baek, J.-H. (2021) · Cancers · doi:10.3390/cancers13030515 · Cited by 14

Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts

Suzuki, Y., Ichinohe, K., Sugawara, A., Kida, S., Murase, S., Zhang, J., Yamada, O., Hattori, T., Oshima, Y., & Kikuchi, H. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.766107 · Cited by 13

Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue

Sommer, U. J., Ebersbach, C., Beier, A.-M. K., Baretton, G. B., Thomas, C., Borkowetz, A., & Erb, H. H. H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.878353 · Cited by 13

Antibody-Based Approaches to Target Pancreatic Tumours

Sorbara, M., Cordelier, P., & Béry, N. (2022) · Antibodies · doi:10.3390/antib11030047 · Cited by 15

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma

Matsui, J. K., Perlow, H. K., Ritter, A. R., Upadhyay, R., Raval, R. R., Thomas, E., Beyer, S. J., Pillainayagam, C. P., Goranovich, J., Ong, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071763 · Cited by 13

Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors

Helderman, N. C., Lucas, M. W., & Blank, C. U. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100374 · Cited by 13

PSGL-1 is a novel tumor microenvironment prognostic biomarker with cervical high-grade squamous lesions and more

Lin, Y., Huang, S., Qi, Y., Xie, L., Jiang, J., Li, H., & Chen, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1052201 · Cited by 13

The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer

Dettorre, G. M., Patel, M., Gennari, A., Pentheroudakis, G. E., Romano, E., Cortellini, A., & Pinato, D. J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100123 · Cited by 14

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach

Grimaud, F., Pénaranda, G., Stavris, C., Rétornaz, F., Brunel, V., Caillères, S., Pegliasco, H., Treut, J. H. L., Grisoni, V., Coquet, E., et al. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s308194 · Cited by 13

Hemostasis and tumor immunity

Cantrell, R., & Palumbo, J. S. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12728 · Cited by 13

Molecular imaging of immune checkpoints in oncology: Current and future applications

Ge, S., Jia, T., Li, J., Zhang, B., Deng, S., & Sang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215896 · Cited by 13

High-resolution molecular atlas of a lung tumor in 3DPreprint

Pentimalli, T. M., Schallenberg, S., León-Periñán, D., Legnini, I., Theurillat, I., Thomas, G., Boltengagen, A., Fritzsche, S., Nimo, J., Ruff, L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.10.539644 · Cited by 13

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model

Wu, Y., Sun, G., Ren, W., Wang, C., Wang, C., Ye, X., Chen, Y., Pang, X., Zhang, Q., Wang, Z. J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03681-8 · Cited by 15

Immunological Changes in Pregnancy and Prospects of Therapeutic Pla-Xosomes in Adverse Pregnancy Outcomes

Devvanshi, H., Kachhwaha, R., Manhswita, A., Bhatnagar, S., & Kshetrapal, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.895254 · Cited by 13

Targeting IL-34/MCSF-1R Axis in Colon Cancer

Monteleone, G., Maresca, C., Colella, M., Pacifico, T., Congiu, D., Troncone, E., & Marafini, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.917955 · Cited by 13

Comparative analysis of PD ‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL ‐2 stimulation data

Austin, D. J., Melhem, M. R., Gandhi, Y., Lu, S. M., & Visser, S. A. G. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12878 · Cited by 12

A multiscale mechanistic model of human dendritic cells for in-silico investigation of immune responses and novel therapeutics discovery

Aghamiri, S. S., Puniya, B. L., Amin, R., & Helikar, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112985 · Cited by 12

Identifying shared transcriptional risk patterns between atherosclerosis and cancer

Baylis, R. A., Gao, H., Wang, F.-D., Bell, C., Luo, L., Björkegren, J., & Leeper, N. (2023) · iScience · doi:10.1016/j.isci.2023.107513 · Cited by 11

Membrane-localized neoantigens predict the efficacy of cancer immunotherapy

Goldberger, Z., Hauert, S., Chang, K., Kurtanich, T. R., Alpar, A. T., Repond, G., Wang, Y., Gomes, S., Krishnakumar, R., Siddarth, P., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101145 · Cited by 14

Gene-activating nanomedicine for the tumor-oriented infiltration of T cells to enhance immunotherapy against solid tumors

Zhang, Y., Zhao, G., Liu, J., Zhang, H., Wang, Y., Luo, Y., Lu, Z.-D., Lu, Z.-D., Shen, S., Du, J., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101992 · Cited by 12

The Role of the Gut Microbiome in Hematological Cancers

Hussein, N., Rajasuriar, R., Khan, A. M., Lim, Y. A. L., & Gan, G. G. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0080 · Cited by 12

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea

Lee, J. Y., Kwon, J. H., Hur, J. Y., Yi, J. H., Lee, J., Cho, H., Do, Y. R., Jo, J., Kang, H. J., Koh, Y., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1042 · Cited by 12

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Giacomo, A. M. D., Schenker, M., Médioni, J., Mańdziuk, S., Majem, M., Gravis, G., Cornfeld, M. J., Ranganathan, S., Lou, S., & Csőszi, T. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102387 · Cited by 12

Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia

Chen, H., Wang, D., Yao, Y., Xiao, Y., Zhao, Z., Zhang, Z., Liu, S., Wang, X., Yang, S., Huang, P., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202411439 · Cited by 12

Matairesinol repolarizes M2 macrophages to M1 phenotype to induce apoptosis in triple-negative breast cancer cells

Chaudhary, A., Patil, P. H., Raina, P., & Kaul-Ghanekar, R. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2425028 · Cited by 13

Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells

Guo, J., Afzal, A., Ahmad, S., Saeed, G., Rehman, A., Saddozai, U. A. K., Liu, L., Guo, S., Ji, X., & Khawar, M. B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550652 · Cited by 12

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer

Li, M., Panet, F., Barberi, V., Salgado, R., Oliveira, M., & Loi, S. (2025) · The Breast · doi:10.1016/j.breast.2025.104545 · Cited by 14

Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy

Lipe, D. N., Rajha, E., Wechsler, A. H., Gaeta, S., Palaskas, N. L., Alhajji, Z., Viets-Upchurch, J. M., & Chaftari, P. S. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.07.014 · Cited by 12

Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers

Schuler, L. A., & Murdoch, F. E. (2021) · Cancers · doi:10.3390/cancers13153725 · Cited by 13

Nanotherapeutics for immune network modulation in tumor microenvironments

Lee, J., Kim, D.-Y., Le, Q., & Oh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.005 · Cited by 12

Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis

Rischpler, C., Rassaf, T., Umutlu, L., Herrmann, K., Schlosser, T., & Totzeck, M. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262301 · Cited by 13

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

Rovers, S., Janssens, A., Raskin, J., Pauwels, P., van Meerbeeck, J. P., Smits, E., & Marcq, E. (2022) · Biomedicines · doi:10.3390/biomedicines10030673 · Cited by 12

Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies

Lombardi, A., Saydere, A., Ungaro, R., Bozzi, G., Viero, G., Bandera, A., Gori, A., & Mondelli, M. U. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.022 · Cited by 12

The Double Engines and Single Checkpoint Theory of Endometriosis

Hsu, C.-F., Khine, A. A., Huang, H.-S., & Chu, T.-Y. (2022) · Biomedicines · doi:10.3390/biomedicines10061403 · Cited by 12

Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model

Ghosh, S., He, X., Huang, W., & Lovell, J. F. (2022) · APL Bioengineering · doi:10.1063/5.0099811 · Cited by 12

Selection of a PD ‐1 blocking antibody from a novel fully human phage display library

Peissert, F., Plüss, L., Giudice, A. M., Ongaro, T., Villa, A., Elsayed, A., Nadal, L., Plaza, S. D., Scietti, L., Puca, E., et al. (2022) · Protein Science · doi:10.1002/pro.4486 · Cited by 11

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma

Kim, S. J., Ryu, K. J., Park, B., Yoon, S. E., Cho, J., Park, Y., & Kim, W. S. (2022) · Cancers · doi:10.3390/cancers14225618 · Cited by 13

Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy

Fu, Y., Huang, Y., Li, P., Wang, L., Tang, Z., Liu, X., Bian, X., Wu, S., Wang, X., Zhu, B., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04767 · Cited by 12

Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis

Choi, J., Kim, N., Nam, R. H., Kim, J. W., Song, C., Na, H. Y., & Kang, G. H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282017 · Cited by 14

Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review

Kut, C., & Kleinberg, L. R. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-94 · Cited by 12

["Immune checkpoint inhibitors in oncology"].

Daëron, M., & Vivier, É. (2021) · PubMed

Meditating on Cancer Management at the Time of Immunotherapy

Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113025

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Weidhaas, J. B. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.030

Immunotherapy for cancer

Lee, A. J. X. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.007 · Cited by 3

Immuno-oncology: A changing paradigm in cancer therapy

Abdel-Rahman, O. M. (2016) · Advances in Modern Oncology Research · doi:10.18282/amor.v2.i6.187 · Cited by 1